drugset
drugset / Trial / NCT01000948

A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer

NCT01000948 ↗

Phase 2 Terminated 24 enrolled Aarhus University Hospital Rigshospitalet, Denmark · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a prospective, open, one-arm, two-centre, Phase II clinical safety pilot-study. The trial is designed to gain initial safety and efficacy-related data on once-daily orally administered ZD4054 10 mg in prior chemotherapy treated patients with metastatic hormone-resistant prostate cancer.

Timeline

Start
2009-10
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Zibotentan Small molecule 10 mg Oral

Indications

metastatic prostate carcinoma